公开(公告)号：US11814431B2

公开(公告)日：2023-11-14

申请号：US16814627

申请日：2020-03-10

Applicant: Five Prime Therapeutics, Inc.

Inventor： Charles Kaplan ,  Derrick Houser ,  Luis Borges ,  Gloria Brattich ,  David Bellovin ,  Felicia Kemp ,  Majid Ghoddusi ,  Nels P. Nielson ,  Kathy Miller ,  Maike Schmidt

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/53 ,  A61P35/00 ,  G01N33/574 ,  A61K39/00

CPC classification number: C07K16/2827 ,  A61P35/00 ,  C07K16/2818 ,  G01N33/57492 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

公开(公告)号：US11447553B2

公开(公告)日：2022-09-20

申请号：US15358756

申请日：2016-11-22

Applicant: Five Prime Therapeutics, Inc.

Inventor： Kristen Pierce ,  Janine Powers ,  Servando Palencia ,  Robert Sikorski ,  Majid Ghoddusi ,  Kartik Krishnan

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/00 ,  G01N33/50 ,  G01N33/574

Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.

公开(公告)号：US20170145102A1

公开(公告)日：2017-05-25

申请号：US15358756

申请日：2016-11-22

Applicant: Five Prime Therapeutics, Inc.

Inventor： Kristen Pierce ,  Janine Powers ,  Servando Palencia ,  Robert Sikorski ,  Majid Ghoddusi ,  Kartik Krishnan

IPC: C07K16/28 ,  C07K16/30

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/55 ,  C07K16/2818 ,  C07K16/2896 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3069 ,  C07K16/3084 ,  C07K2317/34 ,  C07K2317/41 ,  G01N33/5091 ,  G01N33/57407 ,  G01N33/57446 ,  G01N33/57492 ,  G01N2333/71 ,  G01N2800/52

Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.

公开(公告)号：US11306144B2

公开(公告)日：2022-04-19

申请号：US16111064

申请日：2018-08-23

Applicant: Five Prime Therapeutics, Inc.

Inventor： Charles Kaplan ,  Derrick Houser ,  Luis Borges ,  Gloria Brattich ,  David Bellovin ,  Felicia Kemp ,  Majid Ghoddusi ,  Nels P. Nielson ,  Kathy Miller ,  Maike Schmidt

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  G01N33/574 ,  A61K39/00

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

公开(公告)号：US20170145103A1

公开(公告)日：2017-05-25

申请号：US15358941

申请日：2016-11-22

Applicant: Five Prime Therapeutics, Inc.

Inventor： Kristen Pierce ,  Janine Powers ,  Servando Palencia ,  Robert Sikorski ,  Majid Ghoddusi ,  Kartik Krishnan

IPC: C07K16/28 ,  G01N33/574 ,  G01N33/50 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/55 ,  C07K16/2818 ,  C07K16/2896 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3069 ,  C07K16/3084 ,  C07K2317/34 ,  C07K2317/41 ,  G01N33/5091 ,  G01N33/57407 ,  G01N33/57446 ,  G01N33/57492 ,  G01N2333/71 ,  G01N2800/52

Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides. This application also provides methods of predicting response to treatment of cancer, such as bladder or gastric cancer, with FGFR2 inhibitors by determining FGFR2 overexpression and/or gene amplification in tumor cells of cancer subjects before treatment with FGFR2 inhibitors either alone or in combination with immune stimulating agents.

公开(公告)号：US11939383B2

公开(公告)日：2024-03-26

申请号：US17006670

申请日：2020-08-28

Applicant: Five Prime Therapeutics, Inc.

Inventor： Charles Kaplan ,  Alessandro Palumbo ,  Kathy Miller ,  Hangil Park ,  Nerissa Mendoza ,  Majid Ghoddusi

IPC: C07K16/18 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  G01N33/574

CPC classification number: C07K16/2827 ,  G01N33/57492 ,  C07K2317/56 ,  C07K2317/565 ,  G01N2333/70532

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4. The anti-B7-H4 antibodies or antigen-binding fragments thereof are useful, for example in detecting B7-H4. Immunohistochemistry (IHC) can be used to detect B7-H4. The present disclosure also provides methods for treating cancer wherein increased B7-H4 has been detected, by administering a therapeutic anti-B7-H4 antibody or antigen-binding fragment thereof.

公开(公告)号：US20240043542A1

公开(公告)日：2024-02-08

申请号：US18484986

申请日：2023-10-11

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Charles Kaplan ,  Derrick Houser ,  Luis Borges ,  Gloria Brattich ,  David Bellovin ,  Felicia Kemp ,  Majid Ghoddusi ,  Nels P. Nielson ,  Kathy Miller ,  Maike Schmidt

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

CPC classification number: C07K16/2827 ,  C07K16/2818 ,  A61P35/00 ,  G01N33/57492 ,  A61K2039/505

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

公开(公告)号：US20230013293A1

公开(公告)日：2023-01-19

申请号：US17685056

申请日：2022-03-02

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Charles Kaplan ,  Derrick Houser ,  Luis Borges ,  Gloria Brattich ,  David Bellovin ,  Felicia Kemp ,  Majid Ghoddusi ,  Nels P. Nielson ,  Kathy Miller ,  Maike Schmidt

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

公开(公告)号：US20190085080A1

公开(公告)日：2019-03-21

申请号：US16111064

申请日：2018-08-23

Applicant: Five Prime Therapeutics, Inc.

Inventor： Charles Kaplan ,  Derrick Houser ,  Luis Borges ,  Gloria Brattich ,  David Bellovin ,  Felicia Kemp ,  Majid Ghoddusi ,  Nels P. Nielson ,  Kathy Miller ,  Maike Schmidt

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.